T Cell Proliferative Responses of Type 1 Diabetes Patients and Healthy Individuals to Human hsp60 and its Peptides

Abulafia-Lapid, Rivka; Elias, Dana; Raz, Itamar; Keren-Zur, Yael; Atlan, Henri; Cohen, Irun R.

doi:10.1006/jaut.1998.0262

Cited by 123 publications

(83 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In fact, non-diabetic siblings of Type 1 diabetic patients have frequently been shown to respond in a similar way to their Type 1 diabetic relatives than unrelated control subjects. Considering the possibility that clinical onset of Type 1 diabetes could be accompanied by a generalised hyperimmune response [18,52], it should also be considered to include control subjects suffering from chronic inflammation not related to Type 1 diabetes [17]. The T-cell committee of the Immunology of Diabetes Society has recommended a sensitive and reproducible assay for the detection of autoreactive T-cells (Table 3) [17].…”

Section: T-cell Assay Standardizationmentioning

confidence: 99%

The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure

2003

View full text Add to dashboard Cite

Section: T-cell Assay Standardizationmentioning

confidence: 99%

The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure

2003

View full text Add to dashboard Cite

“…Dr. Rivka Abulafia and Professor Itamar Raz of Hadassah University Hospital collaborated with us to show that Type I diabetes patients do make significant T-cell responses to HSP60 and to p277 [44]. These findings paved the way for clinical trials of p277 vaccination therapy in humans.…”

Section: Peptide P277 In Human Type I Diabetesmentioning

confidence: 91%

Peptide therapy for Type I diabetes: the immunological homunculus and the rationale for vaccination

2002

Diabetologia

View full text Add to dashboard Cite

The autoimmune process that produces Type I (insulin-dependent) diabetes mellitus seems to respond favourably to therapeutic vaccination with a peptide of the 60 kDa heat shock protein. This article is a personal review of the observations and the thinking that gave rise to the idea of therapeutic peptide vaccination. The rationale for vaccination therapy is compared to other approaches aimed at specific immunological treatment for autoimmune disease. [Diabetologia (2002)

show abstract

“…[131][132][133] These positive results in NOD mice and the HSP60 T-cell reactivity in recent-onset diabetic patients have highlighted peptide 277 as a possible candidate for Ag-specific clinical studies. 134 In order to stabilize peptide 277 chemically without interfering with its immunomodulatory insulin or pro-insulin respectively. 105 So it seemed as if nasal insulin pushed the immune system toward a more tolerant state.…”

Section: No Effect 109mentioning

confidence: 99%